Inquire Before Buying
Speak to an Analyst 
Request Brochure 
Request CustomizationIMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
Read More
US Cholesterol Lowering Agents Market Report & Forecast: On the Edge of a Patent Cliff
Report Format: PDF+Excel | Report ID: SR112024A275
Buy Now
1. Research Methodology & Market Definitions
2. Executive Summary
3. Epidemiology
3.1 Prevalence of Dyslipidemia
3.2 Diagnosis & Drug Treatment Rates
4. The US Cholesterol Lowering Agents Market
4.1 Current Trends (2005-2010)
4.2 Market Forecast (2011-2016)
5. The US Dyslipidimia Market: Performance of Various Classes
5.1 Statins
5.1.1 Key Trends (2005-2010)
5.1.2 Share of Key Players
5.1.3 Sales & Forecast of Key Molecules
5.1.3.1 Atorvastatin (Lipitor) Historical Sales & Forecast
5.1.3.2 Rosuvastatin (Crestor) Historical Sales & Forecast
5.1.3.3 Simvastatin (Zocor) Historical Sales & Forecast
5.1.3.4 Pravastatin (Pravachol) Historical Sales & Forecast
5.1.3.5 Fluvastatin (Lescol) Historical Sales & Forecast
5.1.3.6 Lovastatin (Mevacor) Historical Sales & Forecast
5.1.3.7 Pitavastatin (Livalo) Historical Sales & Forecast
5.2 Fixed Dose Combinations
5.2.1 Key Trends
5.2.2 Share of Key Players
5.2.3 Sales & Forecast of Key Molecules
5.2.3.1 Ezetimibe/Simvastatin (Vyotrin) Historical Sales & Forecast
5.2.3.2 ER Niacin/Simvastatin (Simcor) Historical Sales & Forecast
5.2.3.3 Atorvastatin/Amlodipine (Caduet) Historical Sales & Forecast
5.2.3.4 ER Naicin/Lapropiprant (Tredaptive) Historical Sales & Forecast
5.2.3.1 Ezetimibe/Atorvastatin (MK-653C) Sales Forecast
5.2.3.2 ER Niacin/Laropiprant/Simvastatin (MK-0524B) Sales Forecast
5.3 Ion Exchange Resins
5.3.1 Key Trends
5.3.2 Share of Key Players
5.3.3 Sales & Forecast of Key Molecules
5.3.3.1 Colesevelam (Welchol) Historical Sales & Forecast
5.3.3.2 Cholestyramine (Questran) Historical Sales & Forecast
5.3.3.3 Colestipol (Colestid) Historical Sales & Forecast
5.4 Fibrates Market
5.4.1 Key Trends
5.4.2 Share of Key Players
5.4.3 Sales & Forecast of Key Molecules
5.4.3.1 Fenofibrate (Tricor) Historical Sales & Forecast
5.4.3.2 Fenofibric Acid (Trilipix) Historical Sales & Forecast
5.4.3.3 Gemfibrozil (Lopid) Historical Sales & Forecast
5.5 Other Cholesterol Triglyceride Regulators
5.5.1 Key Trends
5.5.2 Share of Key Players
5.5.3 Sales & Forecast of Key Molecules
5.5.3.1 Ezetimibe (Zetia) Historical Sales & Forecast
5.5.3.2 Nicotinic Acid (Niacin/Niaspan) Historical Sales & Forecast
5.6 Omega-3 Acid Ethyl Esters (Lovaza)
5.6.1 Key Trends
5.6.2 Share of Key Players
5.6.3 Sales Forecast
5.7 CETP Inhibitors
5.7.1 Sales Forecast for Key Molecules
5.7.1.1 Dalcetrapib (RO4607381/JTT-705) Sales Forecast
5.7.1.2 Anacetrapib (MK-0859) Sales Forecast
6. Genericization in the US Dyslipidemia Market
6.1 Generic Evolution in the US Dyslipidemia Market
6.2 Patent Expiries & Size of the Generic Opportunity
6.3 Forecast for Dyslipidemia Generics
7. Key Company Profile
7.1 Pfizer
7.2 Merck & Co
7.3 Astrazeneca
7.4 Abbott
7.5 Glaxosmithkline
List of Figures
Figure 3 1: US - Number of Dyslipidemia Patients (in 000’s), 2010, 2015 & 2020
Figure 3 2: US - Diagnosed and Drug Treated Dylipidemia Patients (in %) 2010, 2015, 2020
Figure 4 1: US – Cholesterol Lowering Agents Market - Share by Class (in %), 2005-2010
Figure 4 2: US – Cholesterol Lowering Agents Market Forecast - Share by Class (in %), 2011-2016
Figure 5 1: US - Statins Market (in Million US$), 2005-2010
Figure 5 2: US - Statins Market – Share of Key Players (in %), 2005-2010
Figure 5 3: US – Statins Market - Share by Molecule (in %) 2005-2010
Figure 5 4: US - Statins Market Forecast – Share by Molecule (in %), 2011-2016
Figure 5 5: US – Atorvastatin Sales (in Million US$), 2005-2010
Figure 5 6: US – Atorvastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 7: US – Rosuvastatin Sales (in Million US$), 2005-2010
Figure 5 8: US - Rosuvastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 9: US –- Simvastatin Sales (in Million US$), 2005-2010
Figure 5 10: US –Simvastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 11: US - Pravastatin Sales (in Million US$), 2005-2010
Figure 5 12: US - Pravastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 13: US –Fluvastatin Sales (in Million US$), 2005-2010
Figure 5 14: US - Fluvastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 15: US – Lovastatin Sales (in Million US$), 2005-2010
Figure 5 16: US – Lovastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 17: US - Pitavastatin Sales (in Million US$), 2010
Figure 5 18: US –Pitavastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 19: US – Fixed Dose Combinations Market (in Million US$), 2005-2010
Figure 5 20: US - Fixed Dose Combinations Market – Share of Key Players (in %),
Figure 5 21: US – Fixed Dose Combinations Market - Share by Molecule (in %) 2005-2010
Figure 5 22: US - Fixed Dose Combinations Market Forecast - Share by Molecule (in %), 2011-2016
Figure 5 23: US – Ezetimibe/Simvastatin Combination Sales (in Million US$), 2005-2010
Figure 5 24: US – Ezetimibe/Simvastatin Combination Sales Forecast (in Million US$), 2011-2016
Figure 5 25: US – ER Niacin/Simvastatin Combination Sales (in Million US$), 2005-2010
Figure 5 26: US – ER Niacin/Simvastatin Combination Sales Forecast (in Million US$), 2011-2016
Figure 5 27: US –Atorvastatin/Amlodipine Combination Sales (in Million US$), 2005-2010
Figure 5 28: US - Atorvastatin/Amlodipine Combination Sales Forecast (in Million US$), 2011-2016
Figure 5 29: US – ER Naicin/Lapropiprant Combination Sales Forecast (in Million US$), 2011-2016
Figure 5 30: US – Ezetimibe/Atorvastatin Combination Sales Forecast (in Million US$), Launch - 2016
Figure 5 31: US – ER Niacin/Laropiprant/Simvastatin Combination Sales Forecast (in Million US$), Launch -2016
Figure 5 32: US – Ion Exchange Resins Market (in Million US$), 2005-2010
Figure 5 33: US - Ion Exchange Resins Market – Share of Key Players (in %),
Figure 5 34: US – Ion Exchange Resins Market - Share by Molecule (in %) 2005-2010
Figure 5 35: US - Ion Exchange Resins Market Forecast – Share by Molecule (in %), 2011-2016
Figure 5 36: US – Colesevelam Sales (in Million US$), 2005-2010
Figure 5 37: US – Colesevalam Sales Forecast (in Million US$), 2011-2016
Figure 5 38: US – Cholestyramine Sales (in Million US$), 2005-2010
Figure 5 39: US – Cholestyramine Sales Forecast (in Million US$), 2011-2016
Figure 5 40: US – Colestipol Sales (in Million US$), 2005-2010
Figure 5 41: US – Colestipol Sales Forecast (in Million US$), 2011-2016
Figure 5 42: US - Fibrates Market (in Million US$), 2005-2010
Figure 5 43: US - Fibrates Market – Share of Key Players (in %),
Figure 5 44: US – Fibrates Market - Share by Molecule (in %) 2005-2010
Figure 5 45: US - Fibrates Market Forecast - Share by Molecule (in %), 2011-2016
Figure 5 46: US – Fenofibrate Sales (in Million US$), 2005-2010
Figure 5 47: US – Fenofibrate Sales Forecast (in Million US$), 2011-2016
Figure 5 48: US – Fenofibric Acid Sales (in Million US$), 2005-2010
Figure 5 49: US – Fenofibric Acid Sales Forecast (in Million US$), 2011-2016
Figure 5 50: US – Gemfibrozil Sales (in Million US$), 2005-2010
Figure 5 51: US – Gemfibrozil Sales Forecast (in Million US$), 2011-2016
Figure 5 52: US – Cholesterol Triglyceride Regulators Market (in Million US$), 2005-2010
Figure 5 53: US - Cholesterol Triglyceride Regulators Market – Share of Key Players (in %),
Figure 5 54: US – Cholesterol Triglyceride Regulators Market - Share by Molecule (in %) 2005-2010
Figure 5 55: US - Cholesterol Triglyceride Regulators Market Forecast - Share by Molecules (in %), 2011-2016
Figure 5 56: US – Ezetimibe Sales (in Million US$), 2005-2010
Figure 5 57: US – Ezetimibe Sales Forecast (in Million US$), 2011-2016
Figure 5 58: US - Nicotinic Acid Sales (in Million US$), 2005-2010
Figure 5 59: US - Nicotinic Acid Sales Forecast (in Million US$), 2011-2016
Figure 5 60: US – Omega-3 Acid Ethyl Esters Market (in Million US$), 2005-2010
Figure 5 61: US - CETP Inhibitors Market Forecast - Share by Molecules (in %), Launch - 2016
Figure 5 62: US – Dalcetrapib Sales Forecast (in Million US$), Launch - 2016
Figure 5 63: US – Anacetrapib Sales Forecast (in Million US$), Launch - 2016
Figure 6 1: US – Dyslipidemia Market – Patent Expiries of Drugs 2005-2010
Figure 6 2: US – Dyslipidemia Market – Share of Brands & Generics by Volume (in %) 2005-2010
Figure 6 3: US – Dyslipidemia Market – Share of Brands & Generics by Sales (in %) 2005-2010
Figure 6 4: US – Dyslipidemia Market Forecast – Key Patent Expiries, 2011-2016
Figure 6 5: US – Dyslipidemia Market Forecast – Share of Brands and Generics by Volume (in %), 2011-2016
Figure 6 6: US – Dyslipidemia Market Forecast – Share of Brands & Generics by Value, 2011-2016
List of Tables
Table 1 1: US - Dyslipidemia Market: Market Definitions
Table 2 1: US: Dyslipidemia Market Forecast by Class & Molecule (in Million US$), 2010, 2013 & 2016
Table 3 1: US – Diagnosed and Drug Treated Dylipidemia Patients (in 000’s), 2010, 2015, 2020
Table 4 1: US – Cholesterol Lowering Agents Market - Sales by Class (in Million US$), 2005-2010
Table 4 2: US – Cholesterol Lowering Agents Market Forecast - Sales by Class (in Million US$), 2011-2016
Table 5 1: US - Statins Market – Sales of Key Players (in Million US$),
Table 5 2: US – Statins Market - Sales by Molecule (in Million US$), 2005-2010
Table 5 3: US – Statins Market Forecast – Sales By Molecule (in Million US$), 2011-2016
Table 5 4: US - Atorvastatin - Drug Overview
Table 5 5: US: Rosuvastatin - Drug Overview
Table 5 6: US- Simvastatin - Drug Overview
Table 5 7: US- Statins Market: Pravastatin - Drug Overview
Table 5 8: US- Fluvastatin - Drug Overview
Table 5 9: US - Lovastatin - Drug Overview
Table 5 10: US - Pitavastatin - Drug Overview
Table 5 11: US - Fixed Dose Combinations Market – Sales of Key Players (in Million US$),
Table 5 12: US – Fixed Dose Combinations Market - Sales by Molecule (in Million US$), 2005-2010
Table 5 13: US – Fixed Dose Combinations Market Forecast – Sales by Molecule (in Million US$), 2011-2016
Table 5 14: US - Ezetimibe/Simvastatin Combination- Drug Overview
Table 5 15: US- ER Niacin/Simvastatin Combination - Drug Overview
Table 5 16: US - Atorvastatin/Amlodipine Combination - Drug Overview
Table 5 17: US - ER Naicin/Lapropiprant Combination - Drug Overview
Table 5 18: US - Ezetimibe/Atorvastatin Combination - Drug Overview
Table 5 19: US - ER Niacin/Laropiprant/Simvastatin Combination - Drug Overview
Table 5 20: US - Ion Exchange Resins Market – Sales of Key Players (in Million US$),
Table 5 21: US – Ion Exchange Resins Market - Sales by Molecule (in Million US$), 2005-2010
Table 5 22: US – Ion Exchange Resins Market Forecast –Sales by Molecule (in Million US$), 2011-2016
Table 5 23: US - Colesevalam - Drug Overview
Table 5 24: US - Cholestyramine - Drug Overview
Table 5 25: US - Colestipol - Drug Overview
Table 5 26: US - Fibrates Market – Sales of Key Players (in Million US$), 2005-2010
Table 5 27: US – Fibrates Market - Sales by Molecule (in Million US$), 2005-2010
Table 5 28: US – Fibrates Market Forecast – Sales by Molecule (in Million US$), 2011-2016
Table 5 29: US - Fenofibrate - Drug Overview
Table 5 30: US - Fenofibric Acid - Drug Overview
Table 5 31: US - Gemfibrozil - Drug Overview
Table 5 32: US - Cholesterol Triglyceride Regulators Market – Sales of Key Players (in Million US$),
Table 5 33: US – Cholesterol Triglyceride Regulators Market - Sales by Molecule (in Million US$), 2005-2010
Table 5 34: US – Cholesterol Triglyceride Regulators Market Forecast – Sales by Molecule (in Million US$), 2011-2016
Table 5 35: US - Ezetimibe - Drug Overview
Table 5 36: US - Nicotinic Acid - Drug Overview
Table 5 37: US - Omega-3 Acid Ethyl Esters - Drug Overview
Table 5 38: US – Omega-3 Acid Ethyl Esters Market Forecast (in Million US$), 2011-2016
Table 5 39: US – CETP Inhibitors Market Forecast – Sales by Molecules (in Million US$), Launch -2016
Table 5 40: US - Dalcetrapib - Drug Overview
Table 5 41: US: Anacetrapib - Drug Overview
Table 6 1: US – Dyslipidemia Market – Brand & Generic Sales (in Million US$), 2005-2010
Table 6 2: US – Dyslipidemia Market – Sales of Molecules One Year Before Patent expiry (in Million US$), 2011-2016
Table 6 3: US – Dyslipidemia Market Forecast – Brand & Generic Sales (in Million US$), 2011-2016
Purchase options
Benefits of Customization
Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-631-791-1145
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-713-2163
Email: sales@imarcgroup.com
Client Testimonials
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
Read More
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
Read More
Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.
Read More.webp)
We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.
Read More
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
Read More
The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.
Read More
My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.
Read More
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
Read More.webp){kind=logo}
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.
Read More
IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.
Read More